Thirty year old drug is back...Tiny Prana Biotechnology (PRAN) was the talk of the town today after the Company’s Director and Scientific Advisory Board Chairman, Colin Masters presented new evidence that PBT-1 (clioquinol) showed good safety and potential efficacy in Alzheimer’s disease. The data from an extended Phase II trial of PBT-1 were presented at the 8th International Springfield/Montreal Symposium on Advances in Alzheimer’s disease. Prana shares rose $2.68 or 43% to $10.25 at midday trading. Prana trades in Australia and on the Nasdaq Small Cap.
